Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise...

Biogen Inc. Common Stock (BIIB) has a valuation score of 75/100 (strong), profitability score of 62/100 (moderate), financial health score of 87/100 (strong), Piotroski F-Score of 5/9, Altman Z-Score of 3.17 (safe zone), revenue growth of -0.9% YoY.

Neutral

Analyst Consensus

Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations43 analysts · 2026-08-01
9
20
13
Strong Buy 9Buy 20Hold 13Sell 1Strong Sell 0

Recent Market Moves

See all BIIB moves →
DateSessionPriceMoveZ-Score
Aug 4Regular$209.13+3.62%2.41
Biogen Inc. Common Stock (BIIB) Valuation & P/E History →Biogen Inc. Common Stock (BIIB) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →